



Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy [Volume 37, Issue 3, September 2018, Pages 248–256]

Eun Joo Song¹, Kye Hwa Jeong², Young Ae Yang², Jeong-Hoon Lim², Hee-Yeon Jung², Ji-Young Choi², Jang-Hee Cho², Chan-Duck Kim², Yong-Lim Kim², Sun-Hee Park²

¹Department of Internal Medicine, Daehyun Chumdan Geriatric Hospital, Daegu, Korea

²Division of Nephrology and Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea

In the above article (<https://doi.org/10.23876/j.krcp.2018.37.3.248>), there was an error in Figure 3. The authors regret this error, and the corrected figure is now presented below.




Figure 3. Kaplan-Meier analysis of anti-PLA2R antibody level and probability of renal survival (chronic kidney disease stage ≥ 3) (A), cumulative probability of complete remission (B) and spontaneous remission (C).

Anti-PLA2R ab, anti-phospholipase A2 receptor antibody.

The authors would like to apologize for any inconvenience.

Correspondence: Sun-Hee Park

Division of Nephrology and Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea. E-mail: sh-park@knu.ac.kr
 ORCID: <https://orcid.org/0000-0002-0953-3343>

Copyright © 2018 by The Korean Society of Nephrology

© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.